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Abstract 64 
Understanding the intricate pathways modulating appetite and subsequent food intake 65 
is of particular importance considering the rise in obesity incidence across the globe. The 66 
serotonergic system, specifically the 5-HT2C receptor, has shown to be of critical importance in 67 
the regulation of appetite and satiety. The GHS-R1a receptor is another key receptor well-68 
known for its role in the homeostatic control of food intake and energy balance. We recently 69 
showed compelling evidence for an interaction between the GHS-R1a receptor and the 5-HT2C 70 
receptor in an in vitro cell line system heterologously expressing both receptors. Here, we 71 
investigated this interaction further. First, we show that the GHS-R1a/5-HT2C dimer-induced 72 
attenuation of calcium signalling is not due to coupling to GαS, as no increase in cAMP signalling 73 
is observed. Next, flowcytometry fluorescence resonance energy transfer (fcFRET) is used to 74 
further demonstrate the direct interaction between the GHS-R1a receptor and 5-HT2C receptor. 75 
In addition, we demonstrate co-localized expression of the 5-HT2C and GHS-R1a receptor in 76 
cultured primary hypothalamic- and hippocampal rat neurons, supporting the biological 77 
relevance of a physiological interaction. Furthermore, we demonstrate that when 5-HT2C 78 
receptor signalling is blocked, ghrelin’s orexigenic effect is potentiated in vivo. In contrast, the 79 
specific 5-HT2C receptor agonist lorcaserin, recently approved for the treatment of obesity, 80 
attenuates ghrelin-induced food intake. This underscores the biological significance of our in 81 
vitro findings of 5-HT2C receptor-mediated attenuation of GHS-R1a receptor activity. Together, 82 
this study demonstrates, for the first time, that the GHS-R1a/5-HT2C receptor interaction 83 
translates into biological significant modulation of ghrelin’s orexigenic effect. This data 84 
highlights the potential development of a combined GHS-R1a and 5-HT2C receptor treatment 85 
strategy in weight management.  86 
 87 
 88 
  89 
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Introduction 90 
The gastric-derived-peptide ghrelin acts as the endogenous ligand for the growth 91 
hormone secretagogue (GHS-R1a) receptor, which is also known as the ghrelin receptor 1, 2. 92 
Ghrelin is the only known gut-peptide exerting an orexigenic effect via the activation of the 93 
centrally expressed GHS-R1a receptor 3-6 and has thus received much attention as an anti-94 
obesity drug target 7-16. However, despite previous and ongoing drug development efforts, no 95 
weight-loss drugs that target the ghrelin receptor are currently on the market.  96 
Initially, the GHS-R1a receptor was found to function as a homodimer 17, 18. However, 97 
recently, the GHS-R1a receptor has also been shown to heterodimerize with other GPCRs 98 
involved in appetite regulation and food reward (for review see 19), including its truncated 99 
splice variant, the GHS-R1b receptor 18, 20-22, the melanocortin 3 receptor (MC3) and the 100 
dopamine receptors (D1 and D2) 23-27. Moreover, our lab has demonstrated compelling evidence 101 
for a functional interaction between the GHS-R1a and the 5-HT2C receptor 27.  102 
Interestingly, serotonergic signaling has since long been known to be involved in 103 
controlling food intake and to impact on satiety 28-38. Individuals with normal regulated brain 104 
serotonin (5-hydroxytryptamine, 5-HT)  levels are more easily satiated and display a better 105 
control over carbohydrate cravings inhibiting sugar intake more readily 39, 40. Moreover, several 106 
drugs targeting the central serotonergic system, such as sibutramine and fenfluramine, have 107 
been specifically developed to induce satiety, or have been found to reduce food intake as a 108 
secondary effect, such as is the case for the 5-HT2B/2C agonist m-chlorophenylpiperazine (mCPP) 109 
29, 37, 41, 42. Unfortunately, none of these drugs have been without heart and pulmonary 110 
vasculature side-effects, or have been associated with a poor efficacy and other non-specific 111 
effects 33.  112 
The centrally expressed serotonin 2C (5-HT2C) receptor, in particular, has been shown to 113 
stimulate satiety via excitatory neurotransmission 29-34, 43. Indeed, a large amount of literature 114 
has validated the critical role played by the 5-HT2C receptor, which has substantiated this 115 
receptor as a viable target for the development of therapeutics in appetite control and weight 116 
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management 30-38. The recently approved 5-HT2C agonist lorcaserin is the first successful 5-HT2C 117 
receptor-targeting drug to reduce weight in the treatment of obesity 44-47. 118 
Interestingly, the expression of the central 5-HT2C receptor 48, 49 corresponds with the 119 
expression profile of the neuronal circuits expressing the GHS-R1a receptor 50-52, which is a first 120 
requirement for a physical interaction or dimerization. In addition, reciprocal interactions 121 
between the serotonin and ghrelin signalling pathways have been described previously. Indeed, 122 
administration of ghrelin to hypothalamic synaptosomes 53 was shown to inhibit 5-HT release, 123 
as was direct administration of ghrelin to hippocampal slices 54. Similarly, recent data has 124 
demonstrated an increased serotonergic turnover in the amygdala and altered serotonin 125 
receptor mRNA levels (including the 5-HT2C receptor) in the amygdala and dorsal raphe, 126 
following acute central ghrelin administration 55. Moreover, attenuated increases in acylated-127 
ghrelin were observed in response to an overnight fast in mice following pharmacological 128 
increases of brain serotonin levels or direct 5-HT2C receptor agonism 56. In addition, direct 129 
administration of serotonin or the 5-HT2 receptor agonist 5-dimethoxy-4-iodoamphetamine 130 
(DOI) attenuated ghrelin’s orexigenic effect in rats 57. We hypothesize that this serotonin-131 
mediated attenuation of ghrelin signalling is mediated via crosstalk of the GHS-R1a receptor 132 
with the 5-HT2C receptor, potentially in a direct physical interaction. In line with this hypothesis, 133 
we have previously shown a functional interaction between the GHS-R1a and 5-HT2C receptor in 134 
vitro 27, demonstrating an attenuated GHS-R1a signalling following co-expression of the 5-HT2C 135 
receptor, which reinforces the physiological relevance of the GHS-R1a/5-HT2C dimer.  136 
However, although evidence for dimerization in vitro is compelling, in general the 137 
existence of GPCR dimers in native tissue has been questioned because of the paucity of reports 138 
demonstrating an interaction in vivo. In this study, we further investigate the interaction 139 
between the GHS-R1a and 5-HT2C receptor in relation to its function in appetite and we analyse 140 
the significance of the interaction of these two key receptors in vivo. Specifically, the co-localized 141 
expression of endogenous levels of these receptors in neuronal cultures is investigated using a 142 
recently described fluorescein-labelled ghrelin peptide tracer 58, 59. Finally, the effects of specific 143 
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5-HT2C receptor antagonism versus agonism on ghrelin’s orexigenic effect is analysed in mice. 144 
To our knowledge this is the first study to show functional relevance of a specific GHS-R1a and 145 
5-HT2C receptor interaction on food intake behaviour in vivo. This data suggest the potential of 146 
combined GHS-R1a receptor antagonism and 5-HT2C receptor agonism as a novel therapeutic 147 
strategy in weight management.  148 
 149 
Results and Discussion 150 
Fluorescence energy transfer upon co-expression of the GHS-R1a receptor with the 5-HT2C 151 
receptor  152 
Heterodimerization of the GHS-R1a receptor with two variants of the 5-HT2C receptor was 153 
investigated using flow cytometry fluorescence energy transfer (FRET). To this end, Hek293A 154 
cells stably expressing the unedited 5-HT2C receptor or a partially edited isoform, 5-HT2C-VSV-155 
eGFP, both c-terminally fused with an enhanced green fluorescent fusion protein (eGFP), were 156 
transduced with lentiviral vectors expressing the GHS-R1a receptor C-terminally fused with a 157 
red fluorescent tag (lvGHS-R1a-TagRFP). The 5-HT2C receptor is prone to post-transcriptional 158 
RNA editing, which is the enzymatic conversion of an adenosine to inosine residues on 5 specific 159 
nucleotide positions (A, B, C, D, E) in the 2nd intracellular loop and is thought to be associated 160 
with a reduced receptor functioning 60-66. Therefore, we included both the unedited 5-HT2C 161 
receptor and the partly edited 5-HT2C–VSV receptor, which is the most abundantly expressed 5-162 
HT2C receptor isoform in human brain. Indeed, the 5-HT2C–VSV receptor isoform is particularly 163 
abundant in the hypothalamus 65, 67, where an increased 5-HT2C receptor editing has been linked 164 
with changes in feeding behaviour and fat mass 38, 66, 68. Noteworthy increases in FRET levels, as 165 
percentage of tagRFP expression, were observed 72hrs post transduction (Figure 1). Following 166 
lentiviral transduction of Hek293 cells with the lvGHS-R1a-tagRFP vector, 61.6% of cells were 167 
analysed as positive for tagRFP expression (Figure 1, 1st row, column 2), with relatively no FRET 168 
signal (1.6%, Figure 1, 2nd row, column 2), which demonstrates successful lentiviral 169 
transduction. In addition, no tagRFP or FRET signal was observed in Hek293 wild type (Hek293 170 
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wt) cells or Hek293 cells stably expressing 5-HT2C-eGFP or the 5-HT2C-VSV variant (Figure 1, 1st 171 
and 2nd row). Hek cells stably expressing 5-HT2C-eGFP or the 5-HT2C-VSV variant showed an 172 
increase in tagRFP expression of respectively 38.7% and 61.5%, when transduced with the 173 
control-tagRFP vector (Figure 1, 3rd row, column 1 and 2). Similar percentages of 68.3% and 174 
52.2% were observed following transduction with the lvGHS-R1a-tagRFP vector in Hek 5-HT2C-175 
eGFP or the Hek 5-HT2C-VSV-eGFP cells, respectively (Figure 1, 3rd row, column 3 and 4). Finally, 176 
when analysing flow cytometry fluorescence energy transfer as a measure of 177 
heterodimerisation, co-expression of GHS-R1a-tagRFP in Hek293 5-HT2C-eGFP or Hek293 5-178 
HT2C-VSV-eGFP cells increased FRET signal from 1.2% to 12.8% and 1.9% to 30.26% compared 179 
to control-TagRFP vectors, respectively (Figure 1, 4th row). These significant increases in FRET 180 
signal are further evidence of a physical interaction between the GHS-R1a receptor and the 5-181 
HT2C receptor. Interestingly, we consistently found a >2x higher percentage of FRET signal when 182 
the GHS-R1a receptor is co-expressed with the edited 5-HT2C-VSV variant of the receptor 183 
compared to the fully unedited 5-HT2C receptor. This may suggest that 5-HT2C receptor editing 184 
can modulate dimer formation and warrants further investigations. 185 
Co-expression of the 5-HT2C receptor attenuates GHS-R1a-mediated intracellular calcium 186 
mobilization without altering cAMP signalling 187 
The GHS-R1a receptor as well as the 5-HT2C receptor couple to the Gq protein, which leads to 188 
Gq-subunit mediated increase in phospholipase C, which subsequently elevates intracellular 189 
calcium levels. To assess the functional consequences of an interaction of the GHS-R1a receptor 190 
with the 5-HT2C receptor we analysed ligand-mediated downstream signalling consequences 191 
following co-expression of fluorescently tagged receptors. To this end, heterologous cells co-192 
expressing the GHS-R1a-EGFP receptor and the 5-HT2C-RFP receptor were analysed for ligand-193 
mediated intracellular calcium increase as well as intracellular cAMP levels. The dose-194 
dependent ghrelin-mediated intracellular calcium influx in Hek293 cells stably expressing the 195 
GHS-R1a receptor, previously shown to be independent of fluorescent tag (Schellekens, van 196 
Oeffelen et al. 2013), was reduced when co-expressing the 5-HT2C receptor (Figure 2 A). In 197 
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addition, a similar attenuation of the GHS-R1a-mediated intracellular calcium mobilization upon 198 
co-expression of the 5-HT2C receptor was observed when the synthetic GHS-R1a ligand, 199 
MK0677, was used (Figure 2 B). This is in line with our previous study and confirms the 5-HT2C 200 
receptor-mediated attenuation of GHS-R1a receptor signalling, which concurs the interaction 201 
between the two receptors 27. Previously, it has been shown that the GHS-R1a receptor 202 
dimerizes with the dopamine D1 receptor leading to an enhanced dopamine induced c-AMP 203 
accumulation 24 and an attenuation of GHS-R1a-mediated calcium signalling 27. This may suggest 204 
a dimer-induced switch in GHS-R1a receptor G-protein coupling from Gαq to Gαs, which has 205 
been previously suggested for neuronal GHS-R1a receptors expressed in neuropeptide Y (NPY) 206 
cells of the arcuate nucleus of the hypothalamus 69. Thus, we set out to determine if the 207 
attenuated GHS-R1a receptor-mediated calcium mobilization observed here is due to a switch in 208 
G protein coupling from Gαq to Gαs. To this end, we measured cAMP increases in Hek293 cells 209 
expressing single receptors or co-expressing both the GHS-R1a and 5-HT2C receptors (Figure 3). 210 
First, we analysed Hek293 cells transduced with the D1 receptor expressing vectors (lvDRD1-211 
tagRFP) as a positive controls (Figure 3A and B), as the D1 receptor is coupled to the G protein 212 
Gαs, and receptor ligand binding subsequently activates adenylyl cyclase, leading to increasing 213 
intracellular concentrations of the second messenger cAMP. Indeed, a significant increase in 214 
intracellular cAMP was observed following exposure to the D1 agonist, 6,7-ADTN hydrobromide 215 
(0.5nM), in Hek293 cells transiently expressing the D1 receptor following lentiviral transduction 216 
but not in cells stably expressing the 5-HT2C receptor (Figure 3A) or the GHS-R1a receptor 217 
(Figure 3B). No cAMP responses were observed in Hek293 cells transiently expressing the D1 218 
receptor following serotonin (100nM) or ghrelin (100nM) exposure (Figure 3A and B). In 219 
addition, no ligand-mediated cAMP responses were observed in Hek293 cells stably expressing 220 
the 5-HT2C-eGFP receptor (Figure 3A and 3C) or in 5-HT2C-expressing cells transduced with lv-221 
GHS-R1a-tagRFP vectors (Figure 3C). Moreover, no ligand-mediated cAMP response were 222 
observed in Hek-GHS-R1a-EGFP cells (Figure 3B and D) or in Hek-GHS-R1a-EGFP cells 223 
lentivirally transduced to express 5-HT2C-tagRFP receptor (Figure 3D). Similar results were 224 
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obtained in cells co-expressing the GHS-R1a receptor with the partially edited 5-HT2C-VSV 225 
isoform (data not shown). Thus, co-expression of the 5-HT2C receptor with the GHS-R1a 226 
receptor, following lentiviral transductions does not induce intracellular cAMP production and, 227 
hence, does not alter G protein coupling in Hek293 cells.  228 
Co-localization of the 5-HT2C receptor and fluorescein-ghrelin staining ex vivo  229 
Next, endogenous co-expression of the GHS-R1a receptor and the 5-HT2C receptor was 230 
investigated in rat neuronal cultures of the hypothalamus and hippocampus (Figure 4). The 231 
hypothalamus is the main brain region integrating peripheral metabolic information controlling 232 
the homeostatic regulation of appetite and food intake 70, 71. The hippocampus is a brain 233 
structure involved in learning and memory function and has recently been linked with food 234 
intake control 72. In addition, the 5-HT2C receptor is strongly expressed in the hippocampus and 235 
on pro-opiomelanocortin (POMC) expressing neurons in the arcuate nucleus of the 236 
hypothalamus as well as in other hypothalamic regions 48, 49, 73, 74. Moreover, a recent study by 237 
Bonn et al., demonstrates that the 5-HT2C receptor can also be found on NPY producing neurons 238 
75, 76, which was previously not recognized. In addition, a significant number of neurons in the 239 
hippocampus express the GHS-R1a receptor 51, 58, 77-79 as well as do most regions of the 240 
hypothalamus 50-52. Specifically, in the arcuate nucleus, the GHS-R1a receptor is strongly 241 
expressed on NPY neurons, with 94% of the NPY neurons demonstrating GHS-R1a mRNA, but 242 
also on the POMC neurons , albeit only in 8% of the POMC neurons 80. Here, we investigated the 243 
co-localization of endogenously expressed 5-HT2C receptor in primary cultured neurons of rat 244 
day 17 embryos (E17), using immunocytochemistry. Serotonergic neurons develop at E16 after 245 
which mucosal enterochromaffin cells containing the largest store of mammalian serotonin 246 
start to develop 81. Therefore, neurons were cultured from rat pups at E17 to ensure 5-HT2C 247 
receptor expression. Central expression of the GHS-R1a receptor was analysed using a variation 248 
of a recently described method using fluorescein-ghrelin 82, a novel strategy to detect specific 249 
GHS-R1a receptor expression 58. Co-localization of the 5-HT2C receptor and fluorescein-ghrelin 250 
binding was correlated in primary rat hypothalamic cells (Figure 4, upper panel) as well as 251 
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primary cultures of neurons from the hippocampus (Figure 4, bottom panel). Immunostaining 252 
of the 5-HT2C receptor (red) and fluorescein-ghrelin binding (green) was mainly observed in the 253 
cell bodies of both neuronal cultures. In the hypothalamus, positive cells were much less 254 
frequent but most of them co-expressed both receptors. In the hippocampus, both receptors 255 
were expressed at higher levels and cells expressing only one receptor were more frequently 256 
found. Indeed, the insert in the bottom picture shows two cells that are both positive for 257 
fluorescein-ghrelin binding to the GHS-R1a receptor but one of them lacking staining for the 5-258 
HT2C receptor (Figure 4, bottom panel). This data clearly demonstrates the co-localized 259 
endogenous expression of the GHS-R1a and 5-HT2C receptor, which is a first requirement for a 260 
physical interaction between these G-protein coupled receptors in vivo. 261 
Specific 5-HT2C receptor blockade potentiates ghrelin’s orexigenic effect in vivo  262 
Next, we analysed the effect of specific 5-HT2C receptor antagonism on ghrelin’s orexigenic 263 
potential in vivo. Food intake of male C57Bl/6 mice was analysed following intraperitoneal 264 
administration of the specific brain-penetrant 5-HT2C receptor antagonist SB242084, followed 265 
by a second intraperitoneal injection of ghrelin or vehicle (Figure 5). Repeated measures 266 
analysis revealed a significant mean effect of treatment compared to vehicle (F(3,28) = 6.535; p = 267 
0.002) and a significant interaction of time × treatment (F(6.1,46.932)=3.817; p = 0.003). Post 268 
hoc analysis of the cumulative food intake indicated that the significance of ghrelin’s orexigenic 269 
effect compared to vehicle tapers off after the 2 hr time point (Figure 5A). This is in line with 270 
previous findings from our lab and others demonstrating that a single administration of ghrelin 271 
causes an acute increase in food intake which is diminished over time 4, 83. Interestingly, the 272 
significance of the ghrelin-induced increase in food intake was maintained after the 2 hr time 273 
point following SB242084-mediated 5-HT2C receptor antagonism (p<0.01), resulting in a 274 
ghrelin-mediated increase in food intake which was still apparent at 9 hours, while the 5-HT2C 275 
antagonist has no effects on food intake when administered on its own (Figure 5A). We 276 
hypothesize that the 5-HT2C receptor interacts with the GHS-R1a receptor following its 277 
activation by ghrelin, potentially via a dynamic dimerization, and attenuates ghrelin’s orexigenic 278 
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effect, which is in line with our in vitro findings (Figure2 and see 27). Specific 5-HT2C receptor 279 
antagonism maintains the significance of ghrelin’s orexigenic effect following acute 280 
administration. In addition, the interaction on food intake following ghrelin and SB242084 co-281 
administration, compared to ghrelin alone, are individually depicted in bar graphs and clearly 282 
visible at 8 and 24 hours after food placement, but not at 1hr (Figure 5B, C, D). At the 1 hr 283 
timepoint ghrelin’s effect is still significant compared to control and co-administration of the 5-284 
HT2C receptor antagonist here has no additional effect on food intake. Together, these data 285 
indicate that ghrelin-induced increases in food intake can be modulated via specific 5-HT2C 286 
antagonism, resulting in a longer duration of ghrelin’s orexigenic effect. 287 
Specific 5-HT2C receptor agonism attenuates ghrelin’s orexigenic effect in vivo  288 
Finally, we analysed the effect of specific 5-HT2C receptor agonism, using lorcaserin, on ghrelin’s 289 
orexigenic effect in vivo. To this end, cumulative food intake of male C57Bl/6 mice following 290 
subcutaneous administration of lorcaserin with and without intraperitoneal ghrelin was 291 
analysed (Figure 6). Repeated measures analysis revealed a significant mean effect of treatment 292 
compared to vehicle (F(3,29) = 3.308; p = 0.034) but no significant interaction of time × treatment 293 
(F(5.046, 48.775)=0.956; p = 0.454). Again an initial significant increase in food intake was 294 
observed following acute treatment with ghrelin compared to vehicle, which lasted up to 2 295 
hours, after which significance tapers off (Figure 6A, B, C, D). Interestingly, ghrelin’s initial 296 
orexigenic effect was not observed when animals also received the 5-HT2C specific agonist, 297 
lorcaserin, at 3mg/kg. Indeed, when the 5-HT2C receptor is activated using lorcaserin, the acute 298 
orexigenic effect is completely blocked in the first 2 hours. Furthermore, no effect on food intake 299 
was observed with this sub-threshold dose of lorcaserin on its own (Figure 6A). At the 8h 300 
timepoint ghrelin’s orexigenic effect compared to control is no longer observed, but the 301 
combination treatment actually has a significant decreased food intake compared to ghrelin, 302 
reinforcing the  significantly inhibition on ghrelin’s orexigenic effect by 5-HT2C receptor agonism 303 
(Figure 6D).  304 
 305 
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In summary, this study gives compelling in vitro and in vivo evidence, for a central interaction 306 
between GHS-R1a and 5-HT2C receptor signalling, in line with previous findings (Schellekens et 307 
al. 2013 JCB; Hansson et al. 2014 Neuropsychopharm). It is likely that this interaction occurs in 308 
the arcuate nucleus of the hypothalamus, but whether this interaction is via dimerization on 309 
POMC or NPY neurons, where both receptors are expressed, despite GHS-R1a receptor 310 
dominance on NPY and 5-HT2C receptor dominance on POMC neurons, remains to be 311 
determined. However, it is also possible that this interaction extends beyond the homeostatic 312 
hypothalamic regulation of food intake and may involve hedonic feeding behaviour. Indeed, 313 
recent studies have identified the ghrelinergic system as a key player in hedonic food intake 314 
behaviours, including the motivational drive to eat, the rewarding aspects of food intake and the 315 
stress-induced ingestion of palatable foods 84-92. Interestingly, the 5-HT2C receptor has also been 316 
implicated in reward-related behaviours 93, 94, which may explain some overlapping 317 
functionalities with the GHS-R1a receptor including involvement in the hedonic regulation of 318 
food intake. Another possibility to consider is that the interaction is not via a direct physical 319 
interaction but through an indirect mechanism mediated by the control both receptors have on 320 
the mesolimbic dopaminergic system, a key pathway for non-homeostatic feeding 95. It has 321 
previously been shown that 5-HT2C receptor agonism has an inhibitory control on dopaminergic 322 
neurons in the ventral tegmental area (VTA) through the activation of GABAergic interneurons 323 
(for review, see 96). In addition, the GHS-R1a receptor is expressed on dopaminergic neurons in 324 
the VTA, enabling ghrelin to have a direct stimulatory effect on the mesolimbic dopaminergic 325 
system 97. Indeed, detailed investigations into the potential interaction between GHS-R1a and 5-326 
HT2C receptor signalling through the mesolimbic pathway are now warranted.  327 
 328 
Conclusion 329 
Together, this study shows compelling evidence for a functionally relevant interaction 330 
between the GHS-R1a and 5-HT2C receptor. Pharmacological blockade of the 5-HT2C receptor 331 
enhances the duration of ghrelin-mediated increase in food intake in mice (Figure 5), which is in 332 
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line with the attenuation of ghrelin-mediated activation of the GHS-R1a in vitro when the 5-HT2C 333 
receptor is co-expressed (Figure 2). In addition, agonism of the 5-HT2C receptor, blocks ghrelin’s 334 
orexigenic effect in mice (Figure 6), which may partly explain the satiety inducing effects of 335 
therapeutic doses of the 5-HT2C receptor specific agonist, lorcaserin. This data uncovers a novel 336 
mechanism for fine-tuning GHS-R1a receptor-mediated food intake via serotonergic activity. 337 
These findings have important implications for the development of future pharmacological 338 
strategies in weight reduction. A more efficacious weight loss could potentially be achieved 339 
following the combined pharmacotherapeutic targeting of the ghrelinergic appetite signalling 340 
pathway and the 5-HT2C receptor-mediated induction of satiety, thereby enhancing specificity 341 
and reducing side effects. Indeed, a combined pharmacological treatment to target both the 342 
GHS-R1a and 5-HT2C receptor simultaneously might be a novel therapeutic approach in the 343 
treatment of eating disorders and obesity, and future investigations are warranted. In addition, 344 
a potential interaction of the GHS-R1a receptor and the 5-HT2C receptor in reward centers 345 
regulating the hedonic aspects of food intake, including the VTA, is likely to broaden the 346 
application potential of novel ghrelinergic and serotonergic pharmacotherapeutics. 347 
 348 
Methods 349 
Receptor ligands 350 
Ligands were prepared as previously described 27. Briefly, the endogenous ligand of the GHS-351 
R1a receptor, ghrelin (SP-GHRL-1; Innovagen), the non-peptide GHS-R1a receptor agonist, 352 
MK0677 (SP960334C; NeoMPS), 5–hydroxytryptamine (5-HT, H9523; Sigma), the D1 receptor 353 
agonist, 6,7-ADTN hydrobromide (Asc-150, Ascent Scientific), and the GHS-R1a specific inverse 354 
agonist, peptide [D-Arg1, D-Phe5,D-Trp7,9, Leu11]-substance P (SP-analog, #1946; Tocris) were 355 
prepared at a 1mM stock solution in assay buffer, consisting of 1x Hanks balanced salt solution 356 
(HBSS) supplemented with 20mM HEPES. Stock solutions were further diluted in assay buffer to 357 
the required concentration for the in vitro assays. MK-0677 (also known as ibutamoren, L-358 
163,191) is a highly specific and potent full agonist of the GHS-R1a receptor, which can activate 359 
Page 14 of 36
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
     
 
15 
 
signalling pathways at doses ranging from 0.2 – 1.4 nM) and, in vivo, has been shown to potently 360 
induce growth hormone (GH) and cortisol release 17, 98. The brain penetrant 5-HT2C specific 361 
antagonist SB242084 (#2901; Tocris) was prepared in DMSO as 20 mg/ml stock solution. For 362 
the in vivo cumulative food intake experiments stocks of ghrelin and SB242084 were further 363 
diluted in saline. The 5-HT2C specific agonist, (+/-)-lorcaserin hydrochloride (FL32280; 364 
Carbosynth) was directly prepared in sterile saline.  365 
Cell Culture 366 
Human embryonic kidney cells (Hek293A) and were cultured in Dulbecco’s Modified Eagle’s 367 
Medium (DMEM, Invitrogen) containing 4.5 g/L glucose and L-glutamine (Sigma Aldrich, 368 
Ireland), supplemented with 10% heat inactivated foetal bovine serum (FBS). Stably transfected 369 
Hek-GHS-R1a-EGFP, Hek-5-HT2C–EGFP and Hek-5-HT2C–VSV-EGFP cells were cultured in 370 
complete DMEM media supplemented with 300 ng/µl G418 as maintenance antibiotic, as 371 
previously described 27. All cells were maintained at 37°C and 5% CO2 in a humidified 372 
atmosphere to a confluence of >85% after which the cells were resuspended and propagated to 373 
a lower density. 374 
Transfection and lentiviral transduction 375 
Stably transfected Hek293A cell lines were generated following Lipofectamine LTX plus reagent 376 
(Invitrogen) mediated transfections with plasmids constructs expressing either the human GHS-377 
R1a receptor (Accession code: U60179.1), the unedited 5-HT2C-INI receptor (Genecopeia, 378 
H3309; Accession code: NM_000868) or the partly edited 5-HT2C-VSV receptor isoform 379 
(Genecopeia, T0336, Accession code: AF208053.1), as previously described 27, 99. In addition, 380 
Hek293A cells stably expressing the GHS-R1a-EGFP, the 5-HT2C-EGFP or the 5-HT2C-VSV-EGFP 381 
were transduced using lentiviral vectors to co-express the GHS-R1a, 5-HT2C, 5-HT2C-VSV or D1 382 
receptor constructs with a red fluorescent protein tag (RFP), as previously described 27. Cells 383 
were transduced with the GPCR-RFP expressing lentiviral vectors diluted in transduction media, 384 
consisting of DMEM with 2% heat-inactivated FBS, 1% NEAA and an additional 8μg/ml 385 
polybrene® (Sigma; H9268). Stable expression of the EGFP fluorescently-tagged GHS-R1a 386 
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receptors was routinely monitored using flow cytometry and expression levels were not 387 
affected by co-expression of the 5-HT2C-RFP construct following lentiviral transduction (data 388 
not shown). All cell lines were generated following approval and in full accordance with the 389 
Environmental Protection Agency (Ireland) under GMO register number G0331-01.  390 
Flow cytometry fluorescence resonance energy transfer (fcFRET) 391 
Cells were harvested 48 to 72 h after transduction using 37oC trypsin/EDTA, centrifuged and 392 
resuspended in PBS and passed through a cell strainer with 40 µm nylon mesh (BD Biosciences, 393 
#352340) prior to analysis. fcFRET analysis was performed on an LSR II cytometer (BD 394 
biosciences) and the eGFP was excited at 488 nm and detected with a 525/50 nm bandpass 395 
filter, while TagRFP was excited at 561nm and detected with a 610/20 nm bandpass filter. FRET 396 
between eGFP and TagRFP was measured by excitation at 488nm and detection with a 610/20 397 
nm bandpass filter (i.e. excitation of the “donor” but detection of the “acceptor”). For each 398 
sample, 104 cells were analysed. Live cells were gated according to forward and sideward 399 
scattering (FSC/SSC). Non transduced Hek293A cells were used for background correction. Cells 400 
expressing donor or acceptor construct only were used to compensate the signal in the FRET 401 
channel for spectral bleed-through and cross-excitation. Data was analysed using FACSDiva 402 
software (BD biosciences). 403 
Calcium mobilization assay 404 
Receptor-mediated changes in intracellular calcium (Ca2+) were analysed as previously 405 
described 27. Briefly, stably transfected cells were seeded in black 96-well microtiter plates at a 406 
density of 2.5 x 105 cells/ml (2.5 x 104 cells/well) and maintained for ~24hrs at 37°C in a 407 
humidified atmosphere containing 5% CO2. On the day of the assay, growth medium was 408 
aspirated off and cells were incubated with 25 µl of assay buffer (1x Hanks balanced salt 409 
solution, HBSS, supplemented with 20mM HEPES buffer) and 25 µl of Calcium 4 dye (R8141, 410 
Molecular Devices Corporation, Sunnyvale, CA) according to the manufacturer’s protocol. Cells 411 
were pre-treated with 1 µM of the GHS-R1a inverse agonist, peptide [D-Arg1,D-Phe5,D-412 
Trp7,9,Leu11]-substance P (#1946; Tocris), contained in the assay buffer, to inhibit constitutive 413 
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GHS-R1a receptor activity. Addition of agonist (25 µl/well) was performed by the Flexstation II 414 
multiplate fluorometer (Molecular Devices Corporation, Sunnyvale, CA), and fluorescent 415 
readings were taken for 80 seconds in flex mode with excitation wavelength of 485 nm and 416 
emission wavelength of 525 nm. The relative increase in cytosolic calcium [Ca2+] was calculated 417 
as the difference between maximum and baseline fluorescence (Vmax-Vmin; the treatment-418 
associated emission minus the unstimulated baseline emission) and depicted as percentage 419 
relative fluorescent units (RFU) compared to response as elicited by control, 3.3% fetal bovine 420 
serum (FBS). Values resulting from incorrect pipetting by the Flexstation were excluded from 421 
the analysis. Data was analysed using GraphPad Prism software (PRISM 5.0; GraphPAD 422 
Software Inc.). 423 
Cyclic adenosine monophosphate (cAMP) assay 424 
Intracellular 3’,5’-cyclic adenosine monophosphate (cAMP) was investigated 4 days after 425 
transduction of Hek-5-HT2C-INI-EGFP or Hek-5-HT2C-VSV with lentiviral constructs expressing 426 
RFP tagged D1 receptor (lvDR1-tagRFP) using the LANCE Ultra cAMP assay (PerkinElmer; 427 
#TRF0262), according to manufacturer’s instructions. Briefly, 5 µl of 2*105 cell/ml cell 428 
suspension was plated per well in a white 384-well plate (Perkin Elmer; Optiplate 6007291). 429 
Receptor activation was stimulated via the addition of 5 µl per well of the D1 receptor agonists 430 
6,7-ADTN hydrobromide (Ascent Scientific; Asc-150). Following 30 minute incubation at room 431 
temperature, 5 µl per well Eu-cAMP tracer in stimulation buffer and 5 µl per well monoclonal 432 
Ulight-anti-cAMP antibody, were added and incubated for an hour at room temperature, 433 
protected from light. Receptor mediated increases in cAMP competes with the Eu-cAMP tracer 434 
and subsequent decreases in time-resolved fluorescence resonance energy transfer (TR-FRET) 435 
emission was measured at 615 nm and 665 nm in the Synergy 2 Multi-Mode Microplate Reader 436 
(BioTek). A quench correction was performed minimizing false positives and false negatives by 437 
calculating the blank corrected ratio 665 nm/615 nm using the equation: F665,CS = [(F665,S – F 438 
665,BL) x F615,MAX]/F615,S. The blank value is separately measured by adding buffer to the 439 
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wells to obtain blank reading at 665 nm. Data was analysed using GraphPad Prism software 440 
(PRISM 5.0; GraphPAD Software Inc.). 441 
Embryonic primary neuronal cultures 442 
Hypothalamic and hippocampal primary neuronal cultures were established from brains of 443 
embryonic day 17 (E17) Sprague Dawley rats generated at the animal care facility of the 444 
IMBICE. All procedures were carried out in strict accordance with the recommendations in the 445 
Guide for the Care and Use of Laboratory Animals of the National Research Council, USA. The 446 
protocol was approved by the Institutional Animal Care and Use Committee of the IMBICE. 447 
Briefly, pregnant rats were anesthetized and prepared to aseptically remove the embryos. Each 448 
brain was removed from the skull and placed on an ice-cooled petri dish with ventral side up. A 449 
micro-dissection forceps was used to pinch out the hypothalamic region posterior to the optic 450 
chiasm, anterior to the mammillary bodies, and 3 mm deep. With the dorsal side up, a sagittal 451 
cut was made down the midline of the brain separating the left and right hemisphere. The 452 
hippocampi were pinched out from each side of the brain following removal of the brainstem 453 
and white matter. All tissue was harvested in ice-cold Hank’s solution. Afterwards, cells were 454 
dissociated with a solution containing trypsin 0.25 mg/ml (cat#L2700-100, Microvet) and 455 
deoxyribonuclease I from bovine pancreas 0.28 mg/ml (cat# D5025, Sigma Aldrich) at 37 °C for 456 
20 min, then 300 μl of FBS was added to stop the digestion and cells were mechanically 457 
dissociated using several glass pipettes with consecutive smaller tip diameters. Cells were 458 
seeded on 24 x 24 mm glasses (5 x 104 cells/each) previously treated with poly-L-lysine (cat# 459 
P8920, Sigma Aldrich) and laid over 6-well plates. Cells were incubated at 37 °C in a 95 % O2 460 
and 5% CO2 atmosphere with DMEM/F12 1:1 medium supplemented with 10 % FBS, 0.25 % 461 
glucose, 2 mM glutamine (cat#21051-016, Gibco), 3.3 μg/ml insulin (Nordisk Pharm Ind, Inc, 462 
Clayton, North Carolina, United States), 5 U/ml penicillin G sodium salt (Richet, Buenos Aires, 463 
Argentina), 5 μg/ml streptomycin (Richet), 40 μg/ml gentamicin sulfate salt (Richet) and 1 % 464 
vitamin solution (cat#L2112-100, Microvet). On culture day 4, half of the incubation medium 465 
was replaced with medium containing cytosine β-D-arabinofuranoside (AraC) to reach a final 466 
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concentration of 5 μM (cat# C1768, SigmaAldrich). Neuronal cells were cultured for 7-10 days 467 
and then used to perform binding and immunocytochemistry assays. 468 
Fluorescein-ghrelin binding and serotonin receptor 2C immunostaining 469 
An in vitro binding assay was performed using fluorescein-ghrelin(1-18) 82 provided by Dr. 470 
Leonard Luyt from The University of Western Ontario, Canada. Specificity and accuracy of the 471 
fluorescein-ghrelin tracer as a strategy to visualize central GHS-R1a receptor expression has 472 
recently been demonstrated 58. The 5-HT2C receptor was detected with a mouse monoclonal 473 
antibody raised against the C-terminus of the receptor, previously validated for specificity in 474 
literature 100. Briefly, neuronal culture glasses were washed once with HBSS, covered with 400 475 
nM fluorescein-ghrelin in HBSS, incubated at room temperature for 20 min in a humidified 476 
chamber, and subsequently rinsed twice in HBSS. Cells were then fixed with 4% formaldehyde 477 
in phosphate buffered saline (PBS) pH 7.4 for 30 min at 4°C. In order to perform 478 
immunofluorescence staining, cells were treated with blocking solution (3% normal donkey 479 
serum and 0.25% TritonX in PBS) and then incubated with goat anti-fluorescein antibody 480 
conjugated to Alexa Fluor 488 (Molecular Probes, A-11096, 1:100 in blocking solution) for two 481 
days at 4°C and washed with PBS. Afterwards, cells were incubated with mouse anti-5-HT2C 482 
antibody (Santa Cruz, cat# sc-17797, 1:200 in blocking solution) for 24h at 4°C, washed with 483 
PBS, and finally incubated for 1h at room temperature with donkey anti-mouse antibody 484 
conjugated to Alexa Fluor 594 (Molecular Probes,  cat# A21203, 1:1000 in blocking solution) 485 
and rinsed with PBS. Negative controls were generated by omitting the primary or the 486 
secondary antibodies and no staining was found (data not shown). The slides were visualized 487 
within a week and stored at 4˚C. Fluorescent and phase contrast images were acquired with a 488 
Nikon Eclipse 50i microscope and a DS-Ri1 Nikon digital camera. The open-source image editing 489 
software FIJI was used to adjust contrast and brightness of microphotographs and to prepare 490 
the composite panels 101. 491 
Cumulative food intake 492 
Page 19 of 36
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
     
 
20 
 
Male C57Bl/6 mice (Harlan, UK) were housed per four in standard holding cages at the animal 493 
care facility of University College Cork. The holding room temperature (21±1 °C) and humidity 494 
(55±10%) were controlled under a 12-h light/dark cycle (lights on 7.00 AM, lights off 7.00 PM). 495 
Water and food (2018S Teklad Global 18% Protein Rodent Diet) were available ad libitum 496 
throughout the study. The mice were habituated on three independent days to the experimental 497 
settings. Cumulative food intake studies were performed based on protocols described in 498 
previous studies (Asakawa, Inui et al. 2001; Finger, Schellekens et al. 2011). Briefly, the mice 499 
were weighed, single-housed in new cages in the experimental room and habituates for 20 500 
minutes before injections. To investigate the effect of 5-HT2C receptor antagonism on ghrelin’s 501 
orexigenic effect a cohort of 32 mice, n=8 per group, of approximately 11 week old animals were 502 
used. For the first injection, SB242084 (#2901; Tocris) (2.0 mg/kg in saline and 1.0% DMSO) 503 
and vehicle (saline with 1.0% DMSO) and for the second injection ghrelin (SP-GHRL-1; 504 
Innovagen) (200 nmol/kg in saline) and vehicle (saline) were administered via intraperitoneal 505 
(IP) administration (10 µl/gram of body weight). To investigate the effect of 5-HT2C receptor 506 
agonism on ghrelin’s orexigenic effect a cohort of 35 mice, n=7-10 per group, of approximately 507 
10 week old mice were used. First, the dose response effect (0, 1, 3 and 10 mg/kg) of a racemic 508 
mixture of the 5-HT2C receptor agonist, (+/-)-lorcaserin hydrochloride (FL32280; Carbosynth) 509 
on cumulative food intake was established following a 16 hr food restriction (data not shown). 510 
The sub-threshold dose of 3 mg/kg (0.3 mg/ml) was selected for further experiments as no 511 
effect on food intake was observed using this dose for up to 8 hours. For combination 512 
experiment, (+/-)-lorcaserin hydrochloride (FL32280; Carbosynth) (3.0 mg/kg in saline) and 513 
vehicle (saline) were administered subcutaneously (10 µl/gram of body weight) followed by a 514 
second injection ghrelin (Innovagen; SP-GHRL-1) (200 nmol/kg in saline) and vehicle (saline) 515 
via intraperitoneal (IP) administration (10 µl/gram of body weight). Time between the first and 516 
second injection was 15 minutes and pre-weighed chow food pellets were carefully placed in 517 
the experimental cages 20 minutes following the second IP injection. Thereafter, the amount of 518 
food was weighed at regular time intervals (20 min, 40 min, 1 h, 1h30min, 2 h, 3 h, 4 h, 5 h, 6 h, 7 519 
Page 20 of 36
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
     
 
21 
 
h, 8 h, 9 h and 24 h). Animals that crumbled the pellet or wetted the pellet, which were both rare 520 
occasions, were excluded to ensure differences in weight reflect pellet consumed. At the end of 521 
the experiment the mice were placed back in their original cages in the holding room. 522 
Cumulative food intake was analysed using GraphPad Prism software (PRISM 5.0; GraphPAD 523 
Software Inc.). All experiments were conducted in accordance with the European Directive 524 
86/609/EEC, the Recommendation 2007/526/65/EC and approved by the Animal 525 
Experimentation Ethics Committee of University College Cork. 526 
Statistical analysis 527 
Statistical analyses were performed using SPSS software (IBM SPSS statistics 20, Chicago, IL, 528 
U.S.A.). For in vitro assays, significance was determined a two-way ANOVA at a significance level 529 
of p < 0.05. For food intake experiments, significant difference was determined with a general 530 
linear model repeated measurement combined with a one-way ANOVA with LSD post hoc test 531 
for each timepoint. If the data was non-spherical a Huynh-Feldt correction was applied. Graphs 532 
were expressed as mean ± SEM. Statistical significances were depicted as follows: * indicating 533 
p<0.05, ** indicating p<0.01 or *** indicating p<0.001.  534 
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FIGURE LEGENDS 792 
 793 
Figure 1 FRET between the 5-HT2C and GHS-R1a receptor. Hek293A cells stably expressing 794 
the 5-HT2C receptor as an eGFP fusion protein or the partially edited 5-HT2C isoform, 5-HT2C-795 
VSV-eGFP, were transiently transduced with lentiviral vectors expressing control-TagRFP or 796 
GHS-R1a-TagRFP. Cells were analysed 72 hrs post transduction using LSRii flow cytometry. Dot 797 
plots are representative of three independent experiments. Percentages indicate levels of 798 
TagRFP expression (TagRFP vs eGFP plots) or FRET levels as a percentage of TagRFP 799 
expression (FRET vs eGFP plots).  800 
 801 
Figure 2 Co-expression of the 5-HT2C receptor attenuates GHS-R1a-mediated intracellular 802 
calcium mobilization. The ligand-mediated intracellular calcium increase in Hek293A cells 803 
stably expressing the GHS-R1a receptor only (solid bars) was reduced when co-expressing the 804 
5-HT2C receptor (striated bars), following exposure to different concentrations of ghrelin (A) or 805 
different concentrations of the synthetic agonist, MK0677 (B). Intracellular calcium mobilization 806 
was depicted in relative fluorescence units (RFU) as a percentage of maximal calcium increase 807 
as elicited by the control (3.3 % FBS). Graph represents the mean ± SEM of triplicate samples. 808 
Statistical significance of ligand-mediated calcium mobilization obtained in double expressing 809 
cells compared to cells solely expressing the GHS-R1a receptor is denoted as * indicating p<0.05, 810 
** indicating p<0.01 or *** indicating p<0.001. 811 
 812 
Figure 3 Co-expression of the 5-HT2C receptor and the GHS-R1a receptor does not 813 
influence cAMP signalling. The dopamine D1 receptor agonist, 6,7-ADTN hydrobromide (0.5 814 
nM), induces an increase in cAMP in human embryonic cells transiently expressing the D1 815 
receptor following lentiviral transduction (lvDRD1-tagRFP) but not in cells stably expressing 816 
the 5-HT2C receptor (A) or the GHS-R1a receptor (B). Co-expression of the GHS-R1a receptor, 817 
following lentiviral transduction (lvGHS-R1a-EGFP) in cells stably expressing the 5-HT2C 818 
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receptor does not induce intracellular cAMP production (C). Neither does lentiviral co-819 
expression of 5-HT2C receptor (lv5HT2C-EGFP) in cells stably expressing the GHS-R1a receptor 820 
(D). Intracellular basal (nonstimulated) cAMP level was used for comparison (black bars). The 821 
data is depicted as the mean ± SEM with each concentration point performed in triplicate. 822 
Statistical significance is denoted as a= p<0.001 compared to vehicle (-) and b= p<0.001 823 
compared to 5-HT (A) or ghrelin (Ghrl) (B), respectively. 824 
 825 
Figure 4 Co-localization of the 5-HT2C receptor and ghrelin-fluorescein staining in rat 826 
hippocampal and hypothalamic neurons. Primary cultured hypothalamic (top panel) and 827 
hippocampal (bottom panel) cells were shown to express the 5-HT2C receptor, indicated in red, 828 
and to also bind fluorescein-ghrelin, indicated in green. Overlapping expression is indicated in 829 
yellow. Nuclear stain by bisbenzimide is indicated in blue. Data is representative of three 830 
independent staining experiments of primary cultured hippocampal neurons (left and right) 831 
from day 17 rat embryos (E17).  832 
 833 
Figure 5 Specific 5-HT2C receptor antagonism potentiates ghrelin’s orexigenic effect 834 
in vivo. Cumulative food intake (A) and food intake at time-points 1, 8 and 24 hour (B, C, D) 835 
are depicted for ad libitum fed male C57Bl/6 mice following intraperitoneal administration 836 
of the brain-penetrant 5-HT2C receptor antagonist SB242084 (2 mg/kg) or vehicle 1 837 
(saline+ 1% DMSO) followed by ghrelin (200 nmol/kg) or vehicle 2 (saline). Results are 838 
depicted ± SEM. Statistical significant differences compared to Vehicle-Vehicle (A) and 839 
between all groups (B, C, D) at each time point are depicted as * indicating p<0.05, ** 840 
indicating p<0.01 or *** indicating p<0.001, n=8 per group. 841 
 842 
Figure 6 Specific 5-HT2C receptor agonism attenuates ghrelin’s orexigenic effect in 843 
vivo. Cumulative food intake (A) and food intake at time-points 20 min, 1 and 8 hour (B, C, 844 
D) are depicted for ad libitum fed male C57Bl/6 mice following subcutaneous 845 
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administration of the 5-HT2C specific agonist lorcaserin (3 mg/kg) or vehicle 1 (saline; 1% 846 
DMSO) followed by intraperitoneal ghrelin (200 nmol/kg) or vehicle 2 (saline). Results are 847 
depicted ± SEM. Statistical significant differences compared to Vehicle-Vehicle (A) and 848 
between all groups (B, C, D) at each time point are depicted as * indicating p<0.05, ** 849 
indicating p<0.01 or *** indicating p<0.001, n=7-10 per group.  850 
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